ClinicalTrials.gg
RecruitingNCT06660355Updated Aug 5, 2026

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

A Phase 2 interventional study of Ruxolitinib and Prednisone in Chronic Graft-versus-host Disease (cGVHD), sponsored by H. Lee Moffitt Cancer Center and Research Institute. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by H. Lee Moffitt Cancer Center and Research Institute · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing ruxolitinib in Bronchiolitis Obliterans Syndrome — 3 open to participants now, 5 under way, 1 of them phase 3. ruxolitinib · Bronchiolitis Obliterans Syndrome.

Planned enrollment
5th of 12
120 · median 63
Started
2024
with 1 other
Phase 2
6 of 12
1 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
H. Lee Moffitt Cancer Center and Research Institute

Among the 12 studies testing ruxolitinib in Bronchiolitis Obliterans Syndrome, this one is the 5th largest by planned enrollment, is one of 2 that started in 2024, is one of 6 in phase 2, and was the 11th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

3 of the 12 studies testing ruxolitinib in Bronchiolitis Obliterans Syndrome are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing ruxolitinib in Bronchiolitis Obliterans Syndrome, or all of them as a file.
02

Study summary

Allogeneic transplant is potentially curative for hematological malignancies but its use is limited by the development of GVHD. Ruxolitinib now has FDA approval for treatment of chronic GVHD that has failed 1-2 prior lines of therapy based on a prior large, randomized phase III study. Given this evidence of safety and efficacy in the early refractory setting (after prednisone failure), Ruxolitinib represents an ideal agent to test in the primary therapy setting. Here investigators propose a phase 2 randomized study to compare Ruxolitinib to prednisone as a first-line therapy in the treatment of chronic GVHD.

03

Conditions studied

  • Chronic Graft-versus-host Disease (cGVHD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • performance status ≥60%.
  • Patients with a diagnosis of chronic per NIH diagnostic criteria5 who are in need for first systemic therapy as per treating physician's discretion, Overlap chronic GVHD will be allowed.
  • No new immune suppressive therapy added within preceding 2 weeks prior to study enrolment.
  • Able to take oral medications.
  • Participants must have adequate organ and marrow function as defined below:

    1. ≥1,000/mcL
    2. ≥30,000/mcL
    3. ≥ 7 g/dL
    4. ≤ 3 times institutional (ULN) unless attributable to GVH

    d. (SGOT)/ALT(SGPT) ≤5 × institutional ULN unless attributable to GVH e. ≥30 ml/min

  • Women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study drug administration.
  • Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Previously treated with systemic immune suppressive therapy for chronic (where the indication for start of that systemic immune suppressive therapy was chronic GVHD).
  • Patients with or uncontrolled cardiovascular disease, including unstable angina, acute myocardial infarction, or stroke within 6 months, class III or IV heart failure will be excluded.
  • Relapse post- transplant. Molecular relapse or Mixed chimerism or treated relapse in remission may be allowed on case by case basis but needs discussion with the study Chair/PI
  • Active , and will be excluded.
  • Any uncontrolled infection at the time if enrollment will be excluded.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Ruxolitinib.
  • Participants with psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women and lactating women are excluded from this study because of the potential for teratogenic or abortifacient effects and an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Ruxolitinib, breastfeeding should be discontinued if the mother is treated with Ruxolitinib.
  • Current or history of active Tuberculosis.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Ruxolitinib Treatment Arm

    Ruxolitinib is administered as 10 mg orally twice daily in 28-day cycles.

    Drug: Ruxolitinib

  • Active comparator
    Prednisone Treatment Arm

    Prednisone will be started at 1mg/kg/day based on patient current body weight in kilograms.

    Drug: Prednisone

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment Success

    Treatment Success is defined as C7D1 NIH CR/PR without death or new line of immune suppressive therapy and will be estimated for both arms.

    Time frame: 6 months

Secondary outcomes

  1. Treatment Success Rate

    The proportion of subjects who are alive with NIH CR/PR, no new systemic therapy for cGVHD, and \< 0.25 mg/kg/day prednisone at C7D1 with 95% CI for each arm will be estimated.

    Time frame: 6 months

07

Study locations

6 of 6 sites recruiting
  • Univ of Miami - Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
    Recruiting
    • Noa Holtzman, MD · Principal investigator
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Recruiting
    • Farhad Khimani, MD · Principal investigator
    • Melissa Alsina, MD · Sub investigator
    • Nelli Bejanyan, MD · Sub investigator
    • Omar Castaneda Puglianini, MD · Sub investigator
    • Hany Elmariah, MD · Sub investigator
    • Rawan Faramand, MD · Sub investigator
    • Ciara Freeman, MD, PhD · Sub investigator
    • Doris Hansen, MD · Sub investigator
    • Michael Jain, MD, PhD · Sub investigator
    • Aleksandr Lazaryan, MD, PhD · Sub investigator
    • Hien Liu, MD · Sub investigator
    • Frederick Locke, MD · Sub investigator
    • Sayeef Mirza, MD · Sub investigator
    • Asmita Mishra, MD · Sub investigator
    • Taiga Nishihori, MD · Sub investigator
    • Jose Ochoa-Bayona, MD · Sub investigator
    • Lia Perez, MD · Sub investigator
    • Fabiana Perna, MD, PhD · Sub investigator
    • Joseph Pidala, MD, PhD · Sub investigator
  • University of Kansas Cancer Center
    Kansas City, Kansas 66160, United States
    Recruiting
    • Muhammad Umair Mushtaq, MD · Principal investigator
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
    Recruiting
    • Alexander Vartanov, MD · Principal investigator
  • University of Virginia Comprehensive Cancer Center
    Charlottesville, Virginia 22908, United States
    Recruiting
    • Indumathy Varadarajan, MD · Principal investigator
  • Virginia Commonwealth University
    Richmond, Virginia 23219, United States
    Recruiting
    • William Clark, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2028, 48 months after the start.

Of 38 non-industry phase 2 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's planned 48 months is above that.

Counting every sponsor, half of 63 studies reached it within 35 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2024
First posted
Oct 28, 2024
StartActual
Dec 23, 2024
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06660355
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Oct 28, 2024
Start date
Dec 23, 2024
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Aug 5, 2026

Study contacts

Sarah Starr
Contact
Sarah.Starr@moffitt.org
813-745-2690
Farhad Khimani, MD
principal investigator · Moffitt Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion